Industry Science

Published in:
Volume 7 / Year 2013 / Issue 1

Trabectedin + pegylated liposomal doxorubicin (PLD) is back!

Page: 22-23

Abstract:Oncologists have welcomed the return of pegylated liposomal doxorubicin (PLD) after an 18-month halt in production. Patients with recurrent ovarian cancer benefit from PLD as monotherapy or in combination with… Read More »

Go Back Print
Webdesign by I2CT
css.php